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tract infection were also present in sewage sludge. Consistently, strains
from both sources were assigned together into the same phenotypical
clusters.
P1260 Paediatric faecal colonization with extended-spectrum
b-lactamase producing Enterobacteriaceae in northern
Portugal
D. Gonc¸alves °, H. Rodrigues, H. Ferreira (Porto, PT)
Objectives: Our previous work, in faecal colonization in the community,
alerted us for the ﬁnding of extended-spectrum b-lactamase (ESBL)
producers in particular niches, as nursing homes. In some Portuguese
social solidarity institutions, we can ﬁnd a day care centre (DCC)
adjacent to a nursing home facility. In that way, the aim of our study was
the detection and characterization of ESBL producing Enterobacteriaceae
in the faecal ﬂora of children attending DCC, in Northern Portugal.
Methods: Faecal samples of children from few months to 6 years
old, attending two DCC, from the North of Portugal, were collected
from April to July 2009. Samples were suspended in BHI. Isolates
were selected in MacConkey agar with ceftazidime (2mg/L), cefotaxime
(2mg/L), and aztreonam (2mg/L). Lactose fermenters were randomly
selected and susceptibility to antimicrobial agents was determined by
agar diffusion methods. Screening of ESBL producers was performed
by the double disk synergy test and conﬁrmed according to the CLSI.
Identiﬁcation of the selected strains was achieved by API 20 E.
b-lactamases were characterized by isoelectric focusing. Conjugation
assays were performed with Escherichia coli HB101.
Results: Of 105 faecal samples of children attending two day care
centres in the North of Portugal we screened 32 ESBL producing
Enterobacteriaceae isolates: 18 Escherichia coli, 2 Citrobacter freundii,
3 Enterobacter cloacae, 1 Enterobacter aerogenes, 2 Enterobacter
sakazaki, 2 Klebsiella ornithinolytica, 2 Hafnia alvei, 1 Pantoea spp.
and 1 Klebsiella oxytoca, predominantly showing an ESBL of pI> 8
alone or in association with b-lactamases of pIs 5.4, 7.4 and 7.8. Other
ESBLs of pI approximately 8 and 7.6, were also present in some isolates.
ESBL gene was successfully transferred coding a b-lactamase of pI> 8
and 5.4 plus approximately 8.
Conclusion: Our results showed that young children are colonized with
ESBL producing Enterobacteriaceae. Isoelectric points of predominant
b-lactamases, alert for the hypothesis of one successful track of
community dispersion of a putative CTX-M-15, in this young population,
in different combination with other b-lactamases, as in the CTX-M-15
producing ST131 Escherichia coli epidemic clone. The hypothesis of
spread from the neighbour nursing homes to the young population needs
to be assessed by strain relationship determination. This reality might
create a cycle of dispersal of ESBL producers, to the healthy community.
b-lactam activity against Enterobacteriaceae
P1261 Comparative in vitro activity of cefditoren and other
antimicrobials against Enterobacteriaceae causing
community-acquired uncomplicated urinary tract infections
in women: a Spanish nationwide multicentre study
O. Cuevas, E. Cercenado °, M. Gimeno, M. Marin, P. Coronel,
E. Bouza for the Spanish Urinary Tract Infection Study Group (SUTIS)
Objectives: Cefditoren is a third generation orally administered
cephalosporin with a broad spectrum of activity against Gram-positive
and Gram-negative bacterial species. After an oral 400-mg single dose,
the mean concentrations in urine are 186.5mg/L at 2−4 h, and 12.7mg/L
at 8−12 h, and is a potential drug to be used in the treatment of urinary
tract infection (UTI). We performed a multicenter nationwide study
in Spain in order to determine the in vitro activity of cefditoren and
other comparative agents against Enterobacteriaceae causing community-
acquired uncomplicated UTI in women.
Methods: From June 2008 to March 2009, 89 institutions participated in
the study. A total of 2152 Enterobacteriaceae were collected and sent to a
reference laboratory where identiﬁcation and antimicrobial susceptibility
testing was performed against 20 antimicrobials using and automated
microdilution method (MicroScan). Cefditoren MIC’s were determined
by the broth microdilution method (CLSI guidelines) using the same
inoculum.
Results: Microorganisms isolated were E. coli (81.8%), Klebsiella
pneumoniae (7.9%), Proteus mirabilis (5.2%), and others (5.1%).
A total of 51 isolates (2.4%) were extended-spectrum b-lactamase
(ESBL) producers, 3 (0.1%) produced plasmidic AmpC enzymes,
and 64 (2.9%) chromosomal AmpC. The MIC50/MIC90 (mg/L)
of cefditoren against all isolates was 0.12/0.5. Cefditoren inhibited
96.5% of isolates at 1mg/L, and was uniformly active against all
isolates with the exception of strains producing ESBLs or AmpC
enzymes. The MIC50/MIC90 of other antimicrobials were: ampicillin
(AMP) >16/>16; amoxicillin/clavulanic (A/C) 8/4/16/8; cefuroxime
(FUR) 4/8; cefotaxime (CTX) 1/1; ciproﬂoxacin (CIP) 0.12/>2;
cotrimoxazole (SXT) 2/38/>4/76; and fosfomycin (FOS) 16/16.
The respective percentages of resistance were: 61%, 17.2%, 5.5%, 2.3%,
20.2%, 27.4%, and 4.8%.
Conclusions: The activity of cefditoren against Enterobacteriaceae
producing community-acquired uncomplicated UTI in women was
superior to that of AMP, A/C, FUR, CIP, SXT, and similar to that of
FOS.
P1262 Susceptibility of Gram-negative pathogens isolated from
intra-abdominal infections in Europe in 2008–2009 − The
SMART Study
R. Badal °, S. Bouchillon, D. Hoban, A. Johnson, M. Hackel
(Schaumburg, US)
Objectives: The Study for Monitoring Antimicrobial Resistance Trends
(SMART) program has been monitoring activity of ertapenem (Etp),
amikacin (Ak), cefepime (Cpe), cefoxitin (Cfx), ceftazidime (Caz),
ceftriaxone (Cax), ciproﬂoxacin (Cp), imipenem (Imp), levoﬂoxacin
(Lvx), ampicillin-sulbactam (AS), and piperacillin/tazobactam (PT) vs.
Gram-negative bacteria from intra-abdominal infections (IAI) since
2002. This report summarizes susceptibility levels for key IAI pathogens
in Europe during 2008–2009.
Methods: 31 labs in Europe each collected up to 100 consecutive Gram-
negative bacteria/year from IAI in 2008–2009. MICs were determined
by broth microdilution, and interpreted using EUCAST guidelines if
available. Susceptibility rates were determined for species with 10
isolates.
Results: 3209 isolates were collected; however, only those with N10
(3130, 97.5% of the total) were included in this analysis. The remaining
79 isolates represented 35 species. The table below shows % susceptible
for each drug; values 90% are shaded.
Conclusions: E. coli (~50% of all IAI pathogens) was 90% susceptible
vs. only 3 drugs: Imp, Etp, and Ak. K. pneumoniae (~11% of all IAI
pathogens) was 90% susceptible vs. only 2 drugs (Imp and Etp), and
just 1 other (Ak) was >80%. No drug achieved even 80% susceptible
vs. P. aeruginosa. Until deﬁnitive identiﬁcation and susceptibility testing
results are known, options for effective empirical therapy of IAI
in Europe have diminished to include very few (e.g., carbapenems,
amikacin) of the agents evaluated in this study.
Organism N Imp Etp Ak Cpe PT Cax Cfx Caz Lvx Cp AS
Escherichia coli 1563 100 99 92 87 87 85 85 85 76 75 44
Klebsiella pneumoniae 359 92 90 87 75 71 73 74 73 76 71 53
Pseudomonas aeruginosa 280 70 na 76 75 77 na na 79 70 72 na
Enterobacter cloacae 211 99 85 96 77 67 56 56 58 91 87 22
Klebsiella oxytoca 136 99 100 100 94 89 91 94 99 99 96 71
Proteus mirabilis 131 83 100 97 100 99 82 61 63 88 81 1
Acinetobacter baumannii 93 47 na 54 na na na na na 16 16 na
Citrobacter freundii 79 100 100 97 87 78 69 69 68 99 97 50
Morganella morganii 72 83 100 97 100 99 82 61 63 88 81 1
Enterobacter aerogenes 56 93 88 96 84 61 52 54 48 93 93 25
Proteus vulgaris 37 89 100 97 92 97 51 78 84 97 97 54
Serratia marcescens 31 97 97 94 94 84 77 87 97 97 77 19
Stenotrophomonas maltophilia 29 10 7 14 10 10 10 10 38 86 14 na
Citrobacter koseri 21 100 100 100 95 100 95 95 95 95 95 90
Hafnia alvei 21 100 85 95 76 43 33 43 24 100 100 10
Citrobacter braakii 11 100 100 100 91 82 64 64 64 100 100 64
